<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925648</url>
  </required_header>
  <id_info>
    <org_study_id>PICASSO</org_study_id>
    <nct_id>NCT04925648</nct_id>
  </id_info>
  <brief_title>Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction</brief_title>
  <acronym>PICASSO</acronym>
  <official_title>PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's purpose is to understand the appearance of your prostate-specific membrane&#xD;
      antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib&#xD;
      alone or in combination with anti-testosterone drug call darolutamide.&#xD;
&#xD;
      Who is it for? You may be eligible to join this study if you have metastatic prostate cancer&#xD;
      and had a recent PSMA scan showing low PSMA uptake&#xD;
&#xD;
      Study Details:&#xD;
&#xD;
      Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide&#xD;
      600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days.&#xD;
      Participants will be followed up on day 7 of treatment and 30 days after treatment.&#xD;
&#xD;
      It is hoped that this research will provide insight into the mechanism of PSMA expression in&#xD;
      advanced prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our group has previously established a strong interaction between the androgen receptor and&#xD;
      PSMA receptor in both castrate sensitive and castrate resistant prostate cancers that impacts&#xD;
      on the density of PSMA expression. Recent lab studies have also revealed that phospho-SRC&#xD;
      inhibition with drugs such as dasatinib can also modulate PSMA expression, in particular in&#xD;
      combination with androgen signalling inhibition. If so, this can influence both the timing&#xD;
      and use of PSMA PET scans, PSMA based radionuclide therapies and PSMA immunotherapies. In&#xD;
      this study we plan to validate and quantify the change in PSMA PET scan SUV when patients&#xD;
      undergo a 14 days treatment with dasatinib alone or in combination with an androgen&#xD;
      signalling inhibitor (darolutamide).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomised pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To quantify the increase in tumour (standard uptake value) SUV measurements comparing baseline to 2-week PSMA PET scans in men being treated with dasatinib alone or in combination with darolutamide</measure>
    <time_frame>14 days</time_frame>
    <description>Primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after a 14-day course of dasatinib alone or in combination with darolutamide in men with castrate resistant prostate cancer</measure>
    <time_frame>14 days</time_frame>
    <description>Secondary outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dasatinib 100mg once daily orally for 14 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dasatinib 100mg once daily and Darolumatide 600 mg twice daily orally for 14 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100mg once daily orally for 14 Days</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darolutamide</intervention_name>
    <description>Darolumatide 600 mg twice daily orally for 14 Days</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, aged 18 years or older&#xD;
&#xD;
          2. Pathologically confirmed adenocarcinoma of prostate or a clinical presentation&#xD;
             consistent with prostate cancer&#xD;
&#xD;
          3. Metastatic castrate resistant prostate cancer previously confirmed on 68Ga-PSMA-11 and&#xD;
             18F-FDG imaging to be inadequate for future PSMA-directed theranostic treatment by a&#xD;
             nuclear medicine physician based on FDG-discordance (FDG-positive, PSMA-negative sites&#xD;
             of disease) OR low PSMA SUV values within 2 weeks of starting study drug&#xD;
&#xD;
          4. Adequate hematologic and organ function within 14 days before the first study&#xD;
             treatment&#xD;
&#xD;
          5. Castrate levels of testosterone &lt; 1.7 ng/ml&#xD;
&#xD;
          6. Provision of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who cannot lie still for at least 30 minutes or comply with imaging.&#xD;
&#xD;
          2. Previous dasatinib for prostate cancer or other condition, eg CLL&#xD;
&#xD;
          3. Allergy to dasatinib or darolutamide&#xD;
&#xD;
          4. Use of drugs that interact with interact pharmacologically with dasatinib within 1&#xD;
             week of study entry eg Use of CYP3A4 inducers (e.g. dexamethasone, phenytoin,&#xD;
             carbamazepine, rifampicin, phenobarbital or St John's Wort) and use of CYP3A4&#xD;
             substrates with narrow therapeutic index (e.g. astemizole, terfenadine, cisapride,&#xD;
             pimozide, quinidine, bepridil or ergot analogues.&#xD;
&#xD;
          5. Use Concomitant use of H2 antagonists or proton pump inhibitors.&#xD;
&#xD;
          6. Current or previous (within the last 6 months) pleural effusion&#xD;
&#xD;
          7. Use of paracetamol during the study period&#xD;
&#xD;
          8. Subjects may not have any of the following: Clinical evidence of uncontrolled heart&#xD;
             failure, myocardial infarction, or angina within the previous 6 months; prolonged QT&#xD;
             interval Fridericia's (QTcF) &gt; 450msec; history of unstable ventricular arrhythmias&#xD;
             (ventricular tachycardia, ventricular fibrillation, or torsades de pointes);&#xD;
             concomitant use of drugs known to cause torsades de pointes [quinidine, procainamide,&#xD;
             disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins,&#xD;
             clarithromycin, chlorpromazine, haloperidol, mesoridazine,thioridazine, pimozide,&#xD;
             cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,&#xD;
             halofantrine, levomethadyl,pentamidine, sparfloxacin, lidoflazine] (these agents must&#xD;
             have been discontinued at least 7 days prior to starting dasatinib)&#xD;
&#xD;
          9. Subjects may not be enrolled with any of the following: History of a significant&#xD;
             bleeding disorder unrelated to cancer, including diagnosed congenital bleeding&#xD;
             disorders (e.g., von Willebrand's disease), and diagnosed acquired bleeding disorder&#xD;
             within one year (e.g., acquired anti-factor VIII antibodies); GI bleeding from any&#xD;
             cause within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anthony Joshua, FRACP, MBBS, PhD</last_name>
    <phone>+61 293555655</phone>
    <email>Anthony.Joshua@svha.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Kent</last_name>
    <phone>+61 293555611</phone>
    <email>SVHS.CancerResearch@svha.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre, St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
      <phone>0293555611</phone>
      <email>SVHS.CancerResearch@svha.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arun Azad, FRACP, MBBS, PhD</last_name>
      <email>arun.azad@petermac.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Anthony Joshua, FRACP</investigator_full_name>
    <investigator_title>Head of Medical Oncology, The Kinghorn Cancer Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Plan to share participant data with individuals outside this trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

